Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To establish bioequivalence at steady state of:
1)0.375 mg pramipexole extended release tablet q.d. in fasted status versus 0.125 mg
pramipexole Immediate release tablet t.i.d. in fasted status 2)1.5 mg pramipexole extended
release tablet q.d. in fasted status versus 0.5 mg pramipexole Immediate release tablet
t.i.d. in fasted status
To investigate dose proportionality of pharmacokinetics parameters for:
1)pramipexole extended release dosage of 0.375 to 1.5 mg q.d.